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Aim To evaluate the importance of epidermal growth factor re-
ceptor (EGFR) protein overexpression and gene amplification in 
carcinogenesis of glottic cancer.
Method In order to evaluate EGFR expression at protein and 
gene level, immunohistochemical (IHC) analysis and fluorescent 
in situ hybridization (FISH) were performed on tissue microarrays 
of laryngeal tissue (145 samples) – 38 samples of normal mucosa, 
46 samples of hyperplastic lesions, and 61 samples of cancerous 
lesions.
Results Membranous (mEGFR) and cytoplasmic (cEGFR) EGFR ex-
pression was significantly different between the analyzed groups. 
The differences were most striking in the suprabasal-transform-
ing zone. IHC evaluation showed that high and low mEGFR stain-
ing contributed to the differentiation of dysplastic lesions, simple 
hyperplasia, and cancerous tissue, as well as between different 
degrees of atypia in hyperplastic lesions (P < 0.050). EGFR gene 
amplification was not found in simple and abnormal hyperplas-
tic lesions, but it was confirmed in 2/21 atypical hyperplasias, in-
dicating that gene amplification can facilitate identification of 
malignant potential in hyperplastic lesions. In cancerous tissue, 
EGFR gene amplification was found in 8/50 samples. EGFR gene 
amplification was found in preinvasive cancer in one patient. In 
invasive carcinomas, gene amplification was not associated with 
stage or grade. Carcinomas with gene amplification showed sig-
nificantly higher cEGFR expression (basal layer P = 0.003; supra-
basal layer P = 0.002).
Conclusions This study confirmed an increase in EGFR protein 
expression and gene amplification with the increase in biologi-
cal aggressiveness of glottic lesions. A correlation between EGFR 
gene amplification and protein expression was established. Gene 
amplification proved to be an early event in glottic carcinogen-
esis, indicating its importance for glottic cancer prevention, early 
detection, and protocol selection.
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Epidermal growth factor receptor (EGFR), a 170 kDa trans-
membrane tyrosine kinase receptor, is a member of the 
EGFR family of cell surface receptors (1,2). The EGFR gene 
is located on the chromosome 7p12 (1). The most re-
searched family member is human epidermal growth fac-
tor receptor 2 (HER-2), which is the target of routine diag-
nostic and therapeutic protocols for breast cancer (3). Even 
though less investigated than HER-2, EGFR protein is over-
expressed in many solid head and neck tumors. It is con-
nected with advanced and aggressive tumors and poor 
prognoses (1,2,4-6).
The relation between protein overexpression and gene 
amplification still remains unclear. Although immunohis-
tochemical (IHC) protein analysis of EGFR has been exten-
sively researched, there is a lack of studies on gene ampli-
fication which seems to be important for new anti-EGFR 
therapies in some tumor types (2,7-14). Two kinds of drugs 
have become the part of cancer therapy protocols: mono-
clonal antibodies that act against the ligand-binding do-
main and small molecules that inhibit the tyrosine-kinase 
activity of the receptor. They have been approved for use 
in some types of EGFR-dependent cancers (eg, colon, lung, 
and pancreas) (2,7-10).
Understanding the EGFR signaling pathway and its impli-
cation in tumorigenesis is crucial in the selection of pa-
tients who could benefit from EGFR-targeted therapies. 
The selection of patients suitable for treatment is based on 
biomarkers that can predict the effectiveness of new ther-
apeutic agents. Intensive studies of some type of lung can-
cers showed that gene amplification and mutations were 
more precise markers of treatment response than EGFR 
protein expression (8,11,12). Research on colonic cancer 
demonstrated that EGFR gene amplification and protein 
overexpression were insufficient in predicting therapy re-
sponse even though they were linked to prognosis. Pa-
tients demonstrating gene amplification showed better 
response to monoclonal antibody treatment in some stud-
ies, but downstream molecules such as v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homologue seem to be even more 
important in predicting response to therapy (9,13,14).
Although EGFR protein overexpression has been studied 
in glottic lesions, there is a lack of information on gene am-
plification for this specific area. There is the need for fur-
ther research of EGFR involvement in glottic carcinogen-
esis in order to optimize treatment protocols for this tumor 
type. Laryngeal cancer is the most prevalent malignant 
head and neck tumor in the male population in Croatia 
(15), with one of the highest mortality rates among can-
cers of the head and neck region (15,16). The glottic region 
is the most common site of origin of laryngeal cancers. This 
cancer was chosen for research because the follow-up of 
atypical hyperplastic lesions of vocal cords and other pre-
cancerous formations is especially difficult and this cancer 
considerably affects patients’ quality of life.
The aim of this study was to investigate the influence of 
EGFR protein overexpression and gene amplification on 
cancerogenesis of glottic cancer and their possible role in 
improvement of follow-up and treatment protocols of pre-
cancerous and cancerous glottic lesions.
PaTIeNTs aND MeTHoDs
Clinicopathological data
The research was performed on 145 biopsy/resection sam-
ples of glottic tissue from patients treated at the Depart-
ment of Pathology and Otorhinolaryngology of the Clinical 
Hospital Center Rijeka between 2003 and 2008. The study 
was approved by the Ethics Committee of Clinical Hospital 
Center Rijeka and patients signed consent forms before en-
rolment. Based on classic pathohistological findings of he-
matoxylin-eosin slides, 3 main groups were formed: control 
patients (n = 38), patients with hyperplastic lesions (n = 46), 
and patients with cancerous lesions (n = 61). Hyperplastic 
lesions were graded according to the Gale-Kambič-Lenart 
Ljubljana classification (17). Carcinomas were graded and 
staged according to the classification criteria of the World 
Health Organization and the tumor-node-metastasis sys-
tem. Subsequently, they were divided into preinvasive (tu-
mor in situ [Tis]) and invasive, and early (Tis-T1T2N0M0) and 
advanced (all above T2N0M0) carcinomas (18).
The control group comprised patients treated for benign 
glottic lesions (nodule, polyp) who had simple hyperpla-
sia as the greatest mucosal change. Hyperplastic lesions 
included 22 abnormal and 24 atypical hyperplastic lesions. 
All malignant cases were squamous cell carcinomas. Forty-
seven invasive, 14 preinvasive, 32 early, and 27 advanced 
laryngeal carcinomas were analyzed.
There were 123 biopsy samples taken from male patients 
and 22 taken from female patients. The patients were aged 
from 38 to 81 years. Mean age of the control group was 
51.5 ± 12.1, mean age of patients with precancerous le-
sions was 58.1 ± 11.8, and mean age of patients with glot-
tic cancer was 56.9 ± 11.3 years. There were 78% smokers 
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in the control group, 76% smokers among patients with 
precancerous lesions, and 70% of smokers among patients 
with glottic cancer.
Tissue microarray (TMa) construction
Hematoxylin-eosin stained sections of glottic mucosa 
were used to mark the areas with surface epithelial layers, 
avoiding areas of necrosis. Three tissue cores, each 1 mm 
in diameter, were placed in a recipient paraffin block using 
a manual tissue arrayer (Alphelys, Plaisir, France). The final 
TMA blocks contained 38 cores with tissue specimens that 
served as controls, 46 cores with hyperplastic lesions, and 
61 cores of tumor samples. Normal liver tissue was used 
for slide orientation. Cores were spaced at intervals of 0.5 
mm in the x- and y-axes. One section from each TMA block 
was stained with hematoxylin-eosin for morphological as-
sessment. Serial sections were cut from TMA blocks for IHC 
staining. Five micrometers thick sections were placed on 
adhesive glass slides (Capillary Gap Microscope Slides, 75 
μm, Code S2024, DakoCytomation, Glostrup, Denmark), 
left to dry overnight at 37°C, and stored in the dark at 
+4°C.
Immunohistochemical staining and evaluation of eGFR 
protein expression
Following deparaffinization in xylene and rehydration in 
alcohol, heat-induced epitope retrieval was achieved by 
immersing the slides in Tris-EDTA buffer (pH 9.0) and boil-
ing them for 10 minutes in a water bath. Slides were al-
lowed to cool over 45 minutes and then pre-incubated 
for 30 minutes with blocking solution containing normal 
donkey (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
or goat serum (DakoCytomation). Sections were incu-
bated with pre-diluted primary monoclonal antibodies 
for EGFR (EGFR pharmDx, Monoclonal Mouse antihuman 
EGFR [clone2-18C9]IgG1). Antibody immunohistochem-
istry was performed in Dako Autostainer Plus (DakoCyto-
mation Colorado Inc, Fort Collins, CO, USA) according to 
the manufacturer’s protocol. All reagents for automated 
IHC were purchased from DakoCytomation (ChemMate 
TM Detection Kit K5001, ChemMate TM Envision HRP de-
tection Kit K5007). Slides were counterstained with Mayer’s 
hematoxylin, dehydrated, and mounted. Negative control 
slides were prepared by substituting Dako ChemMate anti-
body diluent for a secondary antibody. Moreover, for posi-
tive and negative controls, colonic cancer tissue sections 
overexpressing EGFR and apparent normal colonic muco-
sa were used.
An analysis of EGFR protein expression was performed. 
Membranous and cytoplasmic staining was evaluated. 
Membranous staining (mEGFR) was divided into mem-
brane high – continuous linear and membrane low – dis-
continuous staining. For positive cytoplasmic EGFR (cE-
GFR) staining, an intense homogenous staining of the 
cytoplasm was necessary. There was no cEGFR without 
membrane staining. The cells were analyzed by a meth-
od adjusted to multilayer squamous epithelium, where 
changes occur in the layers. The basal zone was defined as 
cells with stromal contact, the superficial zone represent-
ed surface cells with applanated nuclei, while the supra-
basal zone was defined as the transforming layer between 
them. Cell-counting was performed by 2 pathologists. The 
results were analyzed on automated image analyzer using 
Issa software (VamsTec, Zagreb, Croatia) by an experienced 
pathologist. Statistical analysis was performed counting all 
cells on 0.01 mm2 in defined zones of control, hyperplas-
tic, or cancerous tissue, and calculating the percentages of 
positive cells with mEGFR and cEGFR expressions.
Fluorescent in situ hybridization
After deparaffinization, the slides were pretreated with Par-
affin Pretreatment Kit (Vysis, Downers Grove, IL, USA) using 
protease to digest proteins for 10 minutes. FISH was per-
formed by applying EGFR probes (Vysis), LSI EGFR Spec-
trumOrange and CEP 7 SpectrumGreen for the respective 
centromeric region at chromosome 7. The LSI EGFR Dual 
Color probe hybridizes to the band region 7p12 in Spec-
trum Orange and the CEP 7 to the 7p11.1-q11, 1, D7Z1 lo-
cus in Spectrum Green. Denaturation of the probe mixture 
was performed at 95°C for 5 minutes in Thermobrite (Ab-
bott Molecular Inc, Des Plaines, IL, USA) followed by over-
night hybridization at 37°C. The following day, cover glass 
was removed and slides were washed in post-hybridization 
washing-buffer (Vysis) at 72°C for 2 minutes. After drying, 
DAPI (Vysis) was applied and slides were protected from 
light at -20°C until reading. Automated scanning, capture, 
and scoring of interphase FISH was analyzed by Cytovision 
System (Applied Imaging Corp., San Jose, CA, USA). EGFR 
gene amplification was defined as a ratio between EGFR 
gene (orange) and centromere (green) signals in tumor 
cell nuclei over 2.2 or the presence of EGFR gene clusters.
statistical analysis
Statistical analysis among 3 groups was carried out using 
Kruskal-Wallis or χ2 tests as appropriate. For differences be-
tween single group pairs, the Mann-Whitney test was ap-
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plied. The level of statistical significance was set at P < 0.05. 
Data in tables are given as mean values ± standard devia-
tions or percentages. Data were analyzed using SPSS, ver-
sion 15.0, for Windows (SPSS Inc, Chicago, IL, USA).
ResulTs
Immunohistochemical evaluation of eGFR protein 
expression
The percentage of positive cells found by IHC analysis in 
distinct zones of multilayer squamous epithelium was 
compared within and between the groups (Figure 1-4).
Although all 3 groups of patients had very similar mEGFR 
staining in the basal layer, hyperplastic and cancerous le-
sions group had an increase in high membranous staining 
vs simple hyperplasia of the control group.
The control group (Figure 1A and 2) had mainly weak 
mEGFR staining in the suprabasal layer (67%). In dysplas-
tic lesions compared with simple hyperplasia group, an in-
crease in high mEGFR staining was found (P = 0.001; Mann-
Whitney U-test), as well as between abnormal and atypical 
lesions (P = 0.035; Mann-Whitney U-test). Moreover, supra-
basal mEGFR expression increased from weak to strong 
with the degree of atypia in hyperplastic lesions group. In 
abnormal hyperplastic lesions group (Figure 1B and 3A), 
33.2% of cells showed high mEGFR, as opposed to 51.1% 
Figure 1.
Immunohistochemical (IHC) analysis of epidermal growth factor receptor (eGFR) protein expression in glottic lesions. (A) simple hyperplasia (control 
group) displaying predominantly basal (high and/or low) and suprabasal (mainly low) membranous epidermal growth factor receptor (meGFR) stain-
ing. Gradual increase of meGFR with degrees of atypia from abnormal (B) to atypical hyperplastic lesions (C): in intensity (from low to high) and in extent 
(through epithelial thickness toward superficial layers). meGFR expression in the entire epithelial thickness of preinvasive (D) and invasive (E) glottic can-
cer. (F) striking example of cytoplasmic epidermal growth factor receptor (ceGFR) expression in glottic cancer. all pictures are photographed at magni-
fication ×40, except atypical lesions ( × 20).
Figure 2.
Percentages of membranous (low and/or high) and cytoplasmic positive 
cells for epidermal growth factor receptor (eGFR) in the control group. 
The control group showed mainly membranous staining of basal and su-
prabasal layers. The staining of the suprabasal layer was predominantly 
low. Cytoplasmic staining appeared in very low intensity of basal layers. 
Closed bars – basal layer; open bars – suprabasal layer; and gray bars 
– superficial layer.
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in atypical lesions group (Figure 1C and 3B). Values were 
even higher in cancerous tissue, where 56.5% of cells had 
high mEGFR expression (Figure 1D, 1E, and 4).
In the superficial layer, no high membranous staining was 
noticed in the control group, and the percentage of low 
mEGFR positive cells was lower than 1% (Figure 2). Low 
mEGFR was noticed in 18% of abnormal (Figure 3A) and 
up to 67% of atypical lesions (Figure 3B). In cancerous le-
sions, up to 61% of cells showed low and 20% high mEGFR 
staining (Figure 4).
cEGFR staining in the control group was mainly basal and 
significantly lower than mEGFR staining (2.4%). Basal and 
suprabasal cEGFR expression was lowest in the control 
group, increased in abnormal and atypical hyperplastic le-
sions, and was highest in cancerous lesions group.
In simple hyperplasia and dysplastic lesions group, no su-
perficial cytoplasmic staining was noticed; it appeared 
only in cancerous lesions group (1.3%).
In cancerous lesions group, an increase in mEGFR expres-
sion in the superficial layer was found with increased tu-
mor grade. The number of negative cells in the suprabas-
al layer was significantly higher in gradus 1 than in gradus 
2 (P = 0.023 Mann-Whitney U-test) and in gradus 1 than 
in gradus 3 (P = 0.031 Mann-Whitney U-test). The differ-
ences between cEGFR staining and grade were not ob-
served (Kruskal-Wallis test). There was a borderline signifi-
cant difference of mEGFR positive cells of the superficial 
layer between preinvasive and invasive tumors (P = 0.051; 
Mann-Whitney U-test). A significant difference between 
advanced and early staged tumors was found in highly 
positive basal cells (P = 0.044; Mann-Whitney U-test) and 
weakly positive superficial cells (P = 0.050; Mann-Whitney 
U-test). There were no differences in cEGFR staining be-
tween early and advanced tumor types (Mann-Whitney 
U-test).
EGFR protein expression did not show significant differ-
ences between non-smokers and smokers in precancer-
ous and cancerous lesions. Smokers in the control group 
showed an increase in high mEGFR positive cells in the 
suprabasal transforming zone (P = 0.023; Mann-Whitney 
U-test).
Figure 3.
(A) Percentages of membranous (low and/or high) and cytoplasmic posi-
tive cells for epidermal growth factor receptor (eGFR) in abnormal and 
(B) atypical hyperplastic lesions. Hyperplastic lesions had more positive 
suprabasal cells than the control group (P = 0.001; Mann-Whitney u-test). 
Within this group, a gradual change in membranous staining was noted, 
from weak positive in abnormal hyperplasia to strong positive in atypical 
lesions. The differences were most striking in the suprabasal-transform-
ing zone. superficial layers showed mainly low membranous staining and 
only a small number of cells manifested high staining intensity. Cytoplas-
mic staining was mostly basal and suprabasal, stronger than in the con-
trol group (basal layer P < 0.001; suprabasal layer P < 0.001; Mann-Whitney 
u-test) but weaker than in cancerous lesions group (basal layer P < 0.001; 
suprabasal layer P < 0.001; Mann-Whitney u-test). Closed bars – basal lay-
er; open bars – suprabasal layer; and gray bars – superficial layer.
Figure 4.
Percentages of membranous (low and/or high) and cytoplasmic posi-
tive cells for epidermal growth factor receptor (eGFR) in glottic cancer. 
Membranous epidermal growth factor receptor (meGFR) staining in can-
cerous tissue appeared throughout all layers of squamous epithelium. 
an increase in high meGFR staining was noted, especially in the supra-
basal and superficial layers, in comparison with controls (suprabasal 
layer P < 0.001; superficial layer P < 0.001; Mann-Whitney u-test) and hy-
perplastic lesions (suprabasal layer P = 0.052; superficial layer P = 0.009; 
Mann-Whitney u-test). Cytoplasmic staining was also much stronger 
and appeared even in the superficial layer. Closed bars – basal layer; 
open bars – suprabasal layer; and gray bars – superficial layer.
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FIsH evaluation of eGFR gene amplification
FISH results were successfully obtained for 118 tissue sam-
ples. Failure to obtain results in 27 samples was mainly due 
to the loss of tissue materials during the TMA sectioning 
and hybridization procedure. EGFR gene amplification 
was found in 10 patients: 2 patients with precancerous le-
sions and 8 patients with laryngeal cancer. A significant 
difference in EGFR gene amplification was found between 
the analyzed groups. First, we evaluated 3 main groups 
(P = 0.031 between controls, hyperplastic lesions, and can-
cerous lesions; χ2 test). For better insight in hyperplastic 
lesions, this group was divided into abnormal and atypi-
cal lesions subgroups (P = 0.045 between controls, abnor-
mal hyperplastic lesions, atypical hyperplastic lesions, and 
cancerous lesions; χ2 test, Table 1). All amplified lesions dis-
played 5 or more signals or clusters of EGFR gene (Figure 
5A and B).
There was no amplification in the control group (Figure 5C). 
In hyperplastic lesions group, amplification was detected 
in 2 cases of atypical hyperplasia (9.5%), one in atypical hy-
perplasia that developed into cancer within one month of 
follow-up, and the other in highly atypical dysplasia. The 
amplification was not detected in any case of abnormal 
hyperplasia.
In cancerous lesions group, EGFR gene amplification was 
found in 16% of cases. Some patients had previous biop-
sies. One of them presented with EGFR gene amplification 
in highly atypical hyperplasia prior to malignant transfor-
mation. In another patient, the amplification of the EGFR 
gene appeared in preinvasive cancer. Gene amplification 
was not connected either with tumor stage and grade or 
smoking habits (χ2 test).
Comparison between eGFR protein expression and 
gene amplification
The 10 samples with EGFR gene amplification had high-
er IHC scores of cEGFR expression throughout all layers 
of squamous epithelium (basal layer P = 0.003; suprabasal 
layer P = 0.001; superficial layer P = 0.042; Mann-Whitney 
U-test). Increased values of high mEGFR staining were 
detected in suprabasal (P = 0.069; Mann-Whitney U-test) 
and superficial (P = 0.217; Mann-Whitney U-test) layers of 
10 amplified samples, but they were not significantly in-
creased.
In the group of precancerous lesion samples with and 
without gene amplification, there was no statistical differ-
ence in IHC EGFR protein expression.
In cancerous lesions, patients with and without EGFR gene 
amplification showed a significant difference in cEGFR 
TaBle 1. Number (%) of biopsies and amplification status of 
epidermal growth factor receptor (eGRF) by fluorescent in situ 
hybridization (FIsH) in different glottic lesions
amplification of  
eGFR gene (%)
Group no yes Total
Control  31 (100)  0 (0)  31 (100)
Abnormal hyperplastic lesions  16 (100)  0 (0)  16 (100)
Atypical hyperplastic lesions  19 (90.5)  2 (9.5)  21 (100)
Squamous carcinoma  42 (84.0)  8 (16.0)  50 (100)
Total number of biopsies* 108 (91.5) 10 (8.5) 118 (100)
*P = 0.045 for controls, abnormal hyperplastic lesions, atypical hyper-
plastic lesions and squamous carcinomas (χ2 test).
Figure 5.
Fluorescence in situ hybridization (FIsH) for epidermal growth factor receptor (eGFR) gene in glottic lesions. FIsH was performed by applying DNa 
probes: spectrum orange-labeled for eGFR gene and spectrum Green-labeled centromeric probe for chromosome 7. (A) Increased eGFR gene copy num-
ber in glottic cancer: the score between eGFR gene (orange) and centromere (green) signals in tumor cell nuclei over 2.2. (B) eGFR gene amplification in 
form of clusters. (C) No amplification of eGFR gene in control tissue (magnification ×100).
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staining in the basal (P = 0.003; Mann-Whitney U-test) and 
suprabasal layers (P = 0.002; Mann-Whitney U-test). Signifi-
cant results are shown in Table 2. Amplified cancerous le-
sions also showed increased high mEGFR staining in the 
suprabasal (P = 0.491; Mann-Whitney U-test) and superfi-
cial (P = 0.502; Mann-Whitney U-test) layers, although with-
out significance.
DIsCussIoN
Reports about EGFR gene amplification in head and neck 
tumors are still lacking, especially in laryngeal cancerogen-
esis. Chromosome 7 aberrations have been found using 
FISH analysis of dysplastic and cancerous laryngeal tissue 
and connected with prognosis (19,20), but there has been 
no gene analysis. The significance of EGFR gene amplifica-
tion as a possible mechanism for protein overexpression 
still remains unclear in glottic cancer because of the het-
erogeneous results of different studies (21-23). The EGFR 
gene was discovered more than 20 years ago, but research 
has been stimulated only recently due to new anti-EGFR 
targeted therapeutic strategies (2,7-14).
In this study, TMA technology enabled us to perform a uni-
form analysis of protein expression and gene amplification 
on the same study material (21,22,24) in order to obtain 
better insight into glottic tumor progression and the rela-
tion of these parameters with standard clinicopathologi-
cal data.
Most studies on EGFR protein expression use semiquan-
titative IHC analysis, which is a relatively available and af-
fordable technique, but subjective to the pathologist’s 
experience. There is still a lack of technique standardiza-
tion, staining intensity interpretation, and result evalua-
tion, which sometimes causes difficulty in comparisons of 
results from different laboratories and authors. Some re-
searchers consider only membranous staining as relevant, 
while others also take cytoplasmic staining into account 
and find it even more important for evaluation of tumor 
aggressiveness and prognosis (25-29). Setting cut-off val-
ues is also difficult in evaluation of overexpression in a mul-
tilayer squamous epithelium like the glottic region, where 
changes occur in layers and cannot be analyzed as, for ex-
ample, glandular tissue in well-researched breast cancers 
and pancreatic adenocarcinomas (3,28).
In this study, a more objective IHC evaluation of EGFR pro-
tein expression has been offered. The method is accurate, 
precise, and reproducible, and is more detailed and objec-
tive compared with the semiquantitative analysis, even 
though still dependent on the experience of the patholo-
gist.
In our study, mEGFR expression showed a gradual change 
from negative to weak positive and strong positive through-
out all layers, from control samples and hyperplastic lesions 
to cancerous tissue, with the changes being most striking 
in the suprabasal-transforming zone. These results indicate 
that high and low mEGFR staining can facilitate the differ-
entiation between dysplastic lesions and simple hyperpla-
sia and cancerous tissue, as well as between different de-
grees of atypia among the hyperplastic lesions. A gradual 
increase in cEGFR expression with an increase in dysplasia 
was also observed. Moreover, the study showed a signifi-
cant correlation between protein expression and different 
levels of atypia in hyperplastic lesions, as well as aggres-
siveness (gradus) and stage (early vs advanced) in glottic 
cancer tissue, confirming EGFR as a possible predictor of 
clinical behavior and prognosis in glottic cancer.
In some reports, high levels of EGFR protein expression 
have been reported even in simple and abnormal hyper-
plastic lesions (25,26,29,30). In our study, high EGFR protein 
expression was also found in some control patients and 
patients with abnormal hyperplastic lesions; none of them 
showed gene amplification, which seems to be connect-
ed to the progression of highly atypical lesions into can-
cer tissue. Based on our results and available literature data 
(25,26,30-33), routine IHC analysis of EGFR in follow-up pro-
tocols of glottic lesions is suggested. IHC methodology is 
relatively simple and affordable, but needs standardization. 
This is why a more objective quantitative IHC assessment 
of EGFR protein levels was offered in this research. In cases 
where IHC of EGFR and classical pathohistological analysis 
are inconclusive, we suggest the detection of gene ampli-
TaBle 2. Cytoplasmic epidermal growth factor receptor (ce-
GFR) expression in comparison with eGFR gene amplification 
status*
amplification of eGFR gene 
(mean†±standard deviation)
ceGFR-expression no (n=42) yes (n=8) P
Basal zone 3.25 ± 4.10 5.98 ± 5.06 0.003
Suprabasal zone 2.61 ± 2.31 7.34 ± 4.21 0.002
*Mann-Whitney u-test.
†Mean values of the number of cells on 0.01 mm2 in defined zones of 
squamous cell carcinoma with cytoplasmic epidermal growth factor 
receptor expression.
‡Number of analyzed tissue samples.
377Braut et al: EGFR in Glottic Carcinogenesis
www.cmj.hr
fication by FISH, which could improve the identification of 
lesions at high risk of cancer development. In this way, al-
ready genetically altered tissue, with high probabilities of 
cancer formation, could be diagnosed before it develops 
into cancer.
To the best of our knowledge and available literature data, 
we are the first to report results about EGFR gene ampli-
fication in precancerous lesions. EGFR gene amplification 
was found in high-risk atypical hyperplastic lesions in 2 cas-
es. There was no EGFR gene amplification in simple or ab-
normal hyperplastic lesions. This indicates that EGFR gene 
amplification can facilitate differentiation of precancerous 
lesions with high malignant potential before they develop 
into glottic cancer. We find these results important and be-
lieve they could improve follow-up of hyperplastic lesions, 
prevention, and early detection of laryngeal cancer.
In cancerous lesions, EGFR gene amplification was found 
in 16% of the cases, which is in accordance with the few 
published studies on laryngeal cancer (21,29,34). Some 
of these patients had previous biopsies. One patient dis-
played EGFR gene amplification in highly atypical hyper-
plasia prior to malignant transformation. In another pa-
tient, who showed no EGFR gene amplification in atypical 
hyperplasia, the amplification of the EGFR gene appeared 
in preinvasive cancer. Other patients showing gene ampli-
fication were diagnosed with glottic cancer on their first 
visit and information on EGFR gene status of their hyper-
plastic lesions is lacking. In this research, in already devel-
oped carcinomas, EGFR gene amplification was not con-
nected with stage or grade. The results are similar to those 
of other authors, who found no difference in EGFR gene 
amplification and tumor stage (21) and grade (29,34). This 
indicates that gene amplification seems to be a genotype 
change that happens even before phenotype changes at 
levels of atypical hyperplastic and preinvasive cancerous 
lesions in some cancer types, acting more in pathogenesis 
than in progression of glottic cancer. Even though only a 
small percentage of EGFR protein overexpression could be 
explained by gene amplification, both were found to hap-
pen early in glottic carcinogenesis.
Comparing IHC and FISH results in our tumor samples, an 
increase in cytoplasmic, basal, and suprabasal EGFR protein 
levels in tumors showing EGFR gene amplification was no-
ticed. The only previous study comparing EGFR at protein 
and gene level by IHC and chromogenic in situ hybridiza-
tion on laryngeal tumors was performed by Tsiambas et al 
(29). In contrast to our study, these authors did not observe 
any significant correlation between EGFR protein expres-
sion and gene amplification. Our findings in glottic cancer 
have yet to be confirmed in future trials. Further research 
is needed to evaluate the impact of cEGFR expression and 
gene amplification in glottic cancer, since some authors 
have found that cytoplasmic expression is connected with 
poor prognosis in some tumor types (ie, renal carcinoma 
and pancreatic adenocarcinoma) (27,28). Our research 
was limited to the evaluation of the glottic region and the 
strict relation between EGFR gene and protein expression, 
along with their correlation with classic pathohistological 
findings. EGRF gene mutations in laryngeal carcinogenesis 
and the analysis of nuclear EGFR are planned for future re-
search.
In conclusion, our study demonstrated gene amplifica-
tion as an early event in glottic cancerogenesis at the lev-
els of high-risk atypical hyperplastic lesions and preinva-
sive carcinomas. This finding could improve glottic cancer 
prevention and early detection before genotype changes 
undergo tumor phenotype formation. An association was 
confirmed between mEGFR expression and gene amplifi-
cation in glottic lesions, as well as a significant correlation 
between cEGFR staining and gene amplification in cancer-
ous tissue. The implication of these findings in laryngeal 
carcinogenesis and the impact on prognosis and treat-
ment have yet to be discovered.
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